Callisto Pharmaceuticals, Inc. is has announced the appointment of Dr. Roman Perez-Soler to the company’s Scientific Advisory Board. Dr. Perez-Soler is a nationally and internationally recognized clinical translational researcher in the field of new anticancer drug development, with a strong emphasis in liposome delivery and thoracic malignancies. He holds the position of Gutman Professor of Oncology and Chairman of the Department of Oncology at the Montefiore Medical Center in Bronx, New York, where he is also Associate Director of Clinical Research at the Albert Einstein Cancer Center and Chief of the Division of Medical Oncology at the Albert Einstein College of Medicine.
“We are delighted that Dr. Perez-Soler is joining our Scientific Advisory Board,” said Callisto Pharmaceuticals CEO Dr. Gary S. Jacob. “Dr. Perez-Soler and his clinical team have played an important clinical and laboratory role in the development of many of the newer antitumor agents such as Erbitux and Tarceva. And his early work on Annamycin, a drug that we recently in-licensed from M.D. Anderson Cancer Center, will be particularly invaluable as we plan to begin a Phase IIb clinical trial with this drug in early 2005.”
Dr. Perez-Soler has authored more than 150 research papers and has 15 issued patents. He is a founder of Aronex Pharmaceuticals, Inc., and more recently, a founder of Transave, Inc., a new pharmaceutical company specializing in aerosolized delivery of antitumor agents and antibiotics.
Dr. Perez-Soler received his M.D. degree from the Universidad Autonoma, Barcelona, Spain, where he trained in internal medicine. From 1982 until 1985, Dr. Perez-Soler received further training in medical oncology at the M.D. Anderson Cancer Center in Houston, Texas. He spent the next 13 years at M.D. Anderson reaching the position of Professor of Medicine and Deputy Chairman of the Department of Thoracic/Head and Neck Medical Oncology. In 1998, Dr. Perez-Soler took the position of Associate Director for Clinical and Translational Research at the Kaplan Cancer Center at New York University.
